Mark Rogel

Mark Rogel specializes in patent matters pertaining to biotechnology. His practice includes US and international patent preparation and prosecution, freedom to operate and patentability analyses, and intellectual property due diligence. Mark has experience in a wide range of technologies, such as cellular and molecular biology, immunology, polypeptide and polynucleotide therapeutics, including RNAi and antisense therapeutics, therapeutic antibodies, recombinant vaccines, gene therapy, stem cell therapeutics, diagnostics, drug delivery systems, biological assay development, and biology-based clean energy.

Prior to joining Cooley, he was an associate at Seed Intellectual Property Law Group. As a research associate in the laboratory of Dr. Michael Emerman at the Fred Hutchinson Cancer Research Center, he studied the role of various genes in the life cycle of the human immunodeficiency virus (HIV), and the interaction between HIV particles and dendritic cells.